Monopar Posts Wider Q2 Loss, Insider Trading Plans Adopted Amid NDA Push
MNPR has more than doubled off its 52-week low of $29.18.
Summary
Monopar's Q2 net loss widened to $5.3M ($0.62/share) from $2.5M a year ago, driven by a near-tripling of R&D spend to $4.8M as the company advances its rolling NDA for ALXN1840 in Wilson disease. Cash of $134.3M funds operations through 2027. Separately, six insiders including the CEO and CFO adopted 10b5-1 trading plans covering up to 91,889 shares — a cluster that raises governance questions. The NDA submission, initiated in July, remains on track for completion in the coming months, with commercial buildout underway via key hires. The insider plan adoption adds a layer of uncertainty around management's near-term stock disposition intentions.
At the time of this announcement, MNPR was trading at $115.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $771.7M. The 52-week trading range was $29.18 to $124.82. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.